Is CD10 Antibody Useful in the Diagnosis of Angioimmunoblastic T-Cell Lymphoma?

Mlika, Mona; Helal, Imen; Laabidi, S; Braham, Emna; Mezni, Faouzi El

doi:10.1080/15321819.2014.1001031

Cited by 3 publications

(4 citation statements)

References 17 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings that CD10 in AITL is co-localized with PD-1-positive T-cells but not with PD-L1-positive cells in the tumor microenvironment support the recent studies describing CD10 as a phenotypic marker that specifically identifies the tumor cells in 90% of AITL, including the early cases [43] antibody as a diagnostic marker of AITL [40]. However, further studies correlating with the clinical course will be of interest in determining the biological significance of CD10 in the AITL.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

Tiemann

Samoilova

Atiakshin

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective Programmed Death-1(PD-1) and its ligand PD-L1 are now used as predictive biomarkers to guide clinical decisions. Precise characterization of PD-L1-positive cells may contribute to our knowledge of which patients derive benefit from the PD-L1 blockade therapy. Results To address this issue, we performed immunophenotyping of PD-L1-positive cells in Hodgkin lymphoma and in angioimmunoblastic T-cell lymphoma (AITL) employing multiple immunofluorescent immunolabeling. We found that PD-L1-positive cells and PD-1-positive cells both in Hodgkin lymphoma and in AITL belong to two completely different cell lineages. In both lymphomas, PD-1 was found exclusively in T-lymphocytes, whereas PD-L1 was revealed in the tumor microenvironment cells including macrophages. PD-L1 was also detected in CD30-positive cells in Hodgkin lymphoma but not in AITL. The marker of B-cell lineage, CD20, was not detectable in PD-L1-positive cells both in AITL and in Hodgkin. Our study highlights the importance of comprehensive assessment of PD-1/PD-L1 regulatory pathways for employing PD-L1 as a predictive biomarker in clinical practice. PD-L1-antibody therapy is proven in Hodgkin lymphoma. Comparative immunophenotyping of the PD-1/PD-L1 axis provides a support for attempts to prove this principle also for AITL.

show abstract

Section: Discussionsupporting

confidence: 89%

“…Since it was assumed that CD10 antibody might be useful in the diagnosis of AITL [40], we decided to perform immunofluorescent double staining of PD-L1 and PD-1 vs CD10 in this lymphoma. We found that PD-L1 and CD10 are never co-localized in the same cells ( Supplementary Fig.…”

Section: Resultsmentioning

confidence: 99%

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

Tiemann

Samoilova

Atiakshin

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…The presence of CD10-positive T-cells distinguishes AITL from other unspecified peripheral T-cell lymphomas, where no CD10-positive T cells are present. Some authors reported the utility of CD10 antibody as a diagnostic marker of AITL [40]. However, further studies correlating with the clinical course will be of interest in determining the biological significance of CD10 in the AITL.…”

Section: Discussionmentioning

confidence: 99%

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

et al. 2020

View full text Add to dashboard Cite

Objective: Programmed death-1 (PD-1) and its ligand PD-L1 are now used as predictive biomarkers to guide clinical decisions. Precise characterization of PD-L1-positive cells may contribute to our knowledge of which patients derive benefit from the PD-L1 blockade therapy. Results: To address this issue, we performed immunophenotyping of PD-L1-positive cells in Hodgkin lymphoma and in angioimmunoblastic T cell lymphoma (AITL) employing multiple immunofluorescent immunolabeling. We found that PD-L1-positive cells and PD-1-positive cells both in Hodgkin lymphoma and in AITL belong to two completely different cell lineages. In both lymphomas, PD-1 was found exclusively in T-lymphocytes, whereas PD-L1 was revealed in the tumor microenvironment cells including macrophages. PD-L1 was also detected in CD30-positive cells in Hodgkin lymphoma but not in AITL. The marker of B-cell lineage, CD20, was not detectable in PD-L1-positive cells both in AITL and in Hodgkin. Our study highlights the importance of comprehensive assessment of PD-1/PD-L1 regulatory pathways for employing PD-L1 as a predictive biomarker in clinical practice. PD-L1-antibody therapy is proven in Hodgkin lymphoma. Comparative immunophenotyping of the PD-1/PD-L1 axis provides a support for attempts to prove this principle also for AITL.

show abstract

Metabolic Intermediates in Tumorigenesis and Progression

He¹,

Gao²,

Tang³

et al. 2019

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Traditional antitumor drugs inhibit the proliferation and metastasis of tumour cells by restraining the replication and expression of DNA. These drugs are usually highly cytotoxic. They kill tumour cells while also cause damage to normal cells at the same time, especially the hematopoietic cells that divide vigorously. Patients are exposed to other serious situations such as a severe infection caused by a decrease in the number of white blood cells. Energy metabolism is an essential process for the survival of all cells, but differs greatly between normal cells and tumour cells in metabolic pathways and metabolic intermediates. Whether this difference could be used as new therapeutic target while reducing damage to normal tissues is the topic of this paper. In this paper, we introduce five major metabolic intermediates in detail, including acetyl-CoA, SAM, FAD, NAD + and THF. Their contents and functions in tumour cells and normal cells are significantly different. And the possible regulatory mechanisms that lead to these differences are proposed carefully. It is hoped that the key enzymes in these regulatory pathways could be used as new targets for tumour therapy.

show abstract

Is CD10 Antibody Useful in the Diagnosis of Angioimmunoblastic T-Cell Lymphoma?

Cited by 3 publications

References 17 publications

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

Metabolic Intermediates in Tumorigenesis and Progression

Contact Info

Product

Resources

About